

SHL/SEC/2023

August 11, 2023

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Company Code: 537253

Dear Sir,

Sub. : **Outcome of the 254th Board Meeting held on 11.08.2023.**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Friday, August 11, 2023, the meeting was started at **11.50 a.m. and concluded at 3.05 p.m.**

1. **Approved the Un-Audited Financial Results (both standalone and consolidated) for the 1st quarter of the Financial year 2023-24 ended on June 30, 2023.**
2. Approved appointment of M/s. Link Intime India Private Limited, New Delhi an agency to conduct Remote e-voting/e-voting and Video conferencing for ensuing the 49th Annual General Meeting to be held on Wednesday, September 27, 2023.
3. Approved appointment of Mr. Tara Chand Sharma (FCS-5749 and C.P. No. 4078) Proprietor of M/s. Jain Sharma & Associate, Company Secretaries, Jaipur as Scrutinizer for conducting e-voting for the 49th Annual General Meeting.
4. Fixed Book Closure period from 20.09.2023 to 27.09.2023 for the purpose of ensuing Annual General Meeting to be held on Wednesday, 27.09.2023 at registered office of the Company, New Delhi.
5. Fixed the date of ensuing Annual General Meeting to be held on Wednesday, 27.09.2023 at Registered office at 38E/252A, Vijay Tower, 3rd Floor, Panchsheel Commercial Complex, Shahpur Jat, New Delhi-110049 through video conferencing/other Audio Visual Method and approved the Cut-off date for determining the entitlements of Members to attend and vote at AGM will be September 19, 2023.

Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 E-mail: info@sunilhealthcare.com Web: www.sunilhealthcare.com

CIN No.: L24302DL1973PLC189662



You are requested to take the above information in your record and oblige us.

Thanking you,
Yours sincerely,
for **Sunil Healthcare Limited**



Satyendu Pattanaik
Company Secretary

FCS-7736

Date: 11.08.2023

Place: New Delhi

Encl.: a/a



SUNIL HEALTHCARE LIMITED

Registered Office : 38E/252-A, Viiay Tower, Shahpuria, New Delhi-110049

Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com

CIN : L24302DL1973PLC189662

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

Particulars	Standalone		Year Ended		Consolidated		Year Ended	
	Quarter ended		Standalone		Quarter ended		Consolidated	
	30th June 2023	31st March 2023	30th June 2022	31st March 2023	30th June 2023	31st March 2023	30th June 2022	31st March 2023
	Unaudited	Audited (Refer note. 2)	Unaudited	Audited	Unaudited	Audited (Refer note. 2)	Unaudited	Audited
1 Revenue from Operations	2,213.23	2,030.73	3,408.11	11,182.95	2,250.95	2,126.05	3,340.59	11,049.10
2 Other Income	81.60	47.95	33.53	162.92	118.81	95.70	91.73	449.64
3 Total Income (1+2)	2,294.83	2,078.68	3,441.64	11,345.87	2,369.76	2,221.75	3,432.32	11,498.74
4 Expenses								
a) Cost of Materials consumed	1,223.18	1,191.15	1,253.00	4,984.14	1,223.18	1,191.15	1,253.00	4,984.14
b) Purchase of Stock-in-trade	-	11.72	0.23	16.83	-	11.72	0.23	16.83
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(89.96)	(80.81)	(91.32)	(327.71)	(72.93)	(6.80)	(113.71)	(279.67)
d) Employees benefit expenses	324.45	311.07	390.16	1,477.71	324.45	311.07	390.16	1,477.71
e) Finance Costs	126.64	117.37	81.88	416.75	126.64	117.37	81.88	416.75
f) Depreciation and amortisation	160.78	199.80	163.03	701.00	160.83	199.85	163.07	701.18
g) Other Expenses	648.34	328.01	1,034.66	3,101.29	694.48	346.29	1,075.26	3,233.47
Total Expenses	2,393.43	2,078.31	2,831.64	10,370.01	2,456.65	2,170.65	2,849.89	10,550.41
5 Profit before tax (3-4)	(98.60)	0.37	610.00	975.86	(86.89)	51.10	582.43	948.33
6 Tax Expenses (Net)	(22.99)	5.79	163.25	278.17	(22.72)	6.10	163.93	280.12
a) Current Tax	-	-	-	-	-	-	-	-
i)-Current Tax	-	(7.18)	101.82	167.49	0.27	(6.87)	102.50	169.44
ii)-Tax for Earlier Period	-	-	-	-	-	-	-	-
b) Deferred Tax Charged/(Credit)	(22.99)	12.97	61.43	110.68	(22.99)	12.97	61.43	110.68
7 Profit/(Loss) after tax	(75.61)	(5.42)	446.75	697.69	(64.17)	45.00	418.50	668.21
8 Other Comprehensive Income (OCI)								
a) Items that will not be reclassified to Profit or Loss (net of tax)	-	(4.11)	-	(4.11)	-	(4.11)	-	(4.11)
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	(20.26)	(23.26)	(11.12)	(59.90)
9 Total Comprehensive Income	(75.61)	(9.53)	446.75	693.58	(84.43)	17.63	407.38	604.20
10 Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11 Other Equity	-	-	-	5,147.07	-	-	-	-
12 Earning per share of Rs.10/- each(not annualised)								
(a) Basic (Rs.)	(0.74)	(0.05)	4.36	6.80	(0.63)	0.44	4.08	6.52
(b) Diluted (Rs.)	(0.74)	(0.05)	4.36	6.80	(0.63)	0.44	4.08	6.52

- As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.
- The figures for the quarter ended March 31, 2023 are the balance figures between audited figures for the full financial and published year to date figures up to the third quarter of the previous financial year.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on August 11, 2023

Place: NEW DELHI

Date: 11-08-2023



Anil Khaitan
Chairman cum Managing Director
DIN 00759951

Review Report on the Quarterly Report on the Unaudited Standalone Financial Results for the quarter June 30, 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended.

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter ended June 30, 2023. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Noida (Delhi-NCR)
Date: August 11, 2023



For Singhi & Co.
Chartered Accountants
Firm Reg. No. 302049E

sp
Bimal Kumar Sipani
Partner

Membership No. 088926
UDIN: 23088926BGXBGD2248

Independent Auditor's Review Report on unaudited consolidated financial results for the quarter ended June 30, 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Sunil Healthcare Limited ('the Company/Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2023, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following wholly-owned foreign subsidiaries:
 - a) Sunil Healthcare Mexico Sa De CV
 - b) Sunil Healthcare North America LLC
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.




6. The unaudited consolidated financial results include the interim financial results of two foreign subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect revenue from operation of Rs. 22.15 Lakhs, net loss after tax of Rs. 8.57 Lakhs and total comprehensive income of (Rs. 28.83 Lakhs) for the quarter ended June 30, 2023 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.



For Singhi and Co.
Chartered Accountants
Firm Reg. No. 302049E


Bimal Kumar Sipani
Partner

Place: Noida (Delhi-NCR)
Date: August 11, 2023

Membership No. 088926
UDIN: 23088926BGXBGE4665